Can Stress Cause Postmenopausal Bleeding?
Yes, in some cases, stress can cause postmenopausal bleeding. This is because stress can result in hormonal imbalances which can lead to changes to the vaginal lining. If the lining becomes too thick, thin, or inflamed, it can shed and cause bleeding.
It's important to note, however, that stress is a rare cause of postmenopausal bleeding.
The most common causes include:
a thickened vaginal lining, which can be caused by excess estrogen in the body
cervical polyps, which are noncancerous growths on the cervix
inflammation or thinning of the vaginal lining, caused by low estrogen levels
» Learn more about how postmenopausal bleeding is treated.
When to speak with a doctor about postmenopausal bleeding
You should always speak with a doctor about any vaginal bleeding that occurs after menopause, even if it is just spotting or has only happened once.
In some cases, postmenopausal bleeding can be a sign of uterine cancer. While this is rare, a doctor can run some tests to check for any cancerous cells. Remember, an early diagnosis of cancer can increase the chance of successful treatment and improve the overall outcome.
How can I manage my stress levels?
There are several way you can manage your stress levels, including:
Learn your triggers. It can be helpful to identify what may be triggering your stress and work to reduce these stressors where possible.
Ensure you're getting enough sleep. Not getting enough sleep can often make daily stressors more difficult to manage.
Make time for things you enjoy. Consider scheduling time for activities that bring you joy and allow you to relax.
Seeking support from loved ones. Speaking about your worries with loved ones may help you feel more supported.
If you are finding it difficult to manage your stress levels, consider speaking with a healthcare professional. They can work with you to put together a suitable treatment plan.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
PODD Drug Delivery Conference Announces 2025 Keynotes
The Conference Forum announces the 15th annual PODD Drug Delivery Conference's 2025 keynotes NEW YORK, June 18, 2025 /PRNewswire/ -- Today, PODD: Partnership Opportunities in Drug Delivery conference announced the keynotes for its 15th annual conference which takes place on October 27-28 at the Westin Copley Place in Boston, MA. "In presenting a strategic-level program for R&D scientists and business development professionals, the PODD Conference is committed to securing keynotes who demonstrate excellence in science," said Andrew Goldstein, Senior Conference Producer for the PODD Conference. The PODD 2025 keynotes include: MIT's Dr Robert Langer, a pioneer in the research and development of drug delivery technology, will return as the Annual Keynote to discuss the state of innovation in the drug delivery industry. Dr Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor who drove the development of GLP-1 drugs for obesity will present on the liraglutide and semaglutide story, her approach to scientific development and where drug delivery intersects with her R&D work. Patient Keynote Jimi Olaghere will share his journey as a patient with sickle cell disease before and after receiving CASGEVY, a CRISPR-based therapy, and his mission to make these therapies more accessible for patients globally. Dr Mansoor Amiji, University Distinguished Professor, Northwestern University, will join the PODD Conference as the Endogenous Delivery Zeitgeist. Dr Amiji will present on endogenous targeted delivery strategies to overcome biological barriers and improve efficacy and safety. The PODD speaking faculty includes over 100 executives from both the drug development and delivery industries with over 125 session choices including a full afternoon of drug delivery presentations from established to start-up companies. To learn more about the event, visit About the PODD: Partnership Opportunities in Drug Delivery ConferencePharma, biotech and the drug delivery industries gather annually at PODD to assess delivery needs, latest trends and information on deals, and learn about a wide range of innovative drug delivery technologies that could improve the delivery of various types of drugs. This can include proteins, peptides, oligonucleotides, biologics, small molecules and more. PODD provides business development opportunities through organized networking and a partnering tool for new, emerging and established collaborations. About the Conference ForumThe Conference Forum is a life science industry research firm that develops conferences, podcasts, newsletters and webinars primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. They are committed to creating the best content, promoting the exchange of ideas and solutions among peers, and providing high-quality networking. Learn more about the Conference Forum at For media inquiries, contact:Bre Bugbee-Barrettbre@ View original content: SOURCE Partnership Opportunities in Drug Delivery (PODD)
Forbes
an hour ago
- Forbes
Working With A Bootstrapped Healthcare Marketing Agency: What To Know
Ajay Prasad is the CEO of GMR Web Team, a full-service healthcare digital marketing agency focused on patient acquisition and retention. A strong digital presence is now essential for all healthcare practices aiming to thrive and connect with patients. When seeking a marketing partner, you'll encounter both large agencies with external funding partners as well as smaller bootstrapped agencies. You may have questions about the resources and reliability of bootstrapped firms compared to larger organizations with more monetary resources. Let's explore the value a bootstrapped agency can offer your practice and what you should consider if you choose to work with one. At its core, a bootstrapped healthcare digital agency is one that has grown and sustained itself primarily through its own revenue generation, without relying on significant external investment like venture capital. This often translates to a few key characteristics: • Resourcefulness and efficiency: Bootstrapped agencies tend to thrive on smart resource allocation and lean operations. They understand the value of every dollar and often prioritize delivering maximum impact with focused strategies. • Client-centric focus: Sustainable growth for a bootstrapped agency hinges on client satisfaction and long-term relationships. This often fosters a deep commitment to understanding and achieving your practice's specific goals. • Potential for specialization: Many bootstrapped agencies carve out a niche and develop deep expertise in specific areas of healthcare marketing, such as SEO for local patient acquisition, social media engagement for building community trust or content marketing tailored to patient education. • Direct leadership involvement: You'll often find that the founders and senior team members are directly involved in client strategy and execution at bootstrapped agencies, providing a level of personalized attention that can be less common in larger, more hierarchical organizations. • Expertise rooted in experience: The founders and teams at bootstrapped agencies often bring years of valuable experience in healthcare marketing. They may have intentionally chosen a self-funded path to maintain control over their vision and focus on delivering specialized expertise without the pressures of external investors. • Agility in a rapidly evolving digital landscape: The digital marketing world is constantly changing. Bootstrapped agencies, often with flatter structures and less bureaucratic processes, can be more nimble in adapting to new algorithm updates, emerging platforms and evolving patient behaviors. Ultimately, the success of your marketing partnership hinges on the agency's ability to understand your goals, develop effective strategies, execute them flawlessly and deliver measurable results. Whether an agency is funded by investors or its own revenue stream is less important than its expertise, its understanding of the healthcare market and its commitment to your success. If you're thinking about working with a bootstrapped agency, look for these crucial skills and offerings: Look for an agency that demonstrates a genuine understanding of the healthcare industry, including compliance regulations (like the Health Insurance Portability and Accountability Act), patient privacy concerns and the unique patient journey within your area of care. Request detailed case studies and speak to current or former clients (when possible and respecting privacy) to gauge the agency's experience and its ability to deliver tangible results for similar healthcare practices. Ensure the agency has clear communication processes, provides regular and transparent reporting on key performance indicators, and fosters collaborative partnerships. Inquire about the agency's approach to staying up to date on the latest digital marketing trends and its ability to adapt strategies based on performance data and evolving market conditions. Choose an agency whose values, communication style and overall approach resonate with your practice's culture. A strong partnership built on mutual understanding and trust is crucial for long-term success. Focus on the overall value proposition an agency offers—its expertise, personalized attention and potential return on investment—rather than just the cost of services. A bootstrapped agency might offer competitive pricing due to lower overhead, but ensure its expertise aligns with your needs. Partnering with a bootstrapped digital marketing agency can be a strategic move for your healthcare practice. But don't let the funding model be the sole determinant. Instead, prioritize a thorough evaluation of the agency's healthcare knowledge, track record, communication style and overall value proposition to find the right fit for your practice's unique needs and aspirations. Forbes Agency Council is an invitation-only community for executives in successful public relations, media strategy, creative and advertising agencies. Do I qualify?
Associated Press
an hour ago
- Associated Press
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
NORTH CHICAGO, Ill., June 18, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, head-to-head study evaluating the tolerability, safety and efficacy of atogepant (QULIPTA® / AQUIPTA®, 60 mg once daily) compared to the highest tolerated dose of topiramate (50, 75 or 100 mg/day) in adult patients with a history of four or more migraine days per month.1 The study met the primary endpoint of treatment discontinuation due to adverse events (AEs), demonstrating that atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, had fewer discontinuations due to AEs than topiramate, an anticonvulsant medication also approved for migraine prevention. Over the 24-week double-blind treatment period, discontinuation due to AEs was significantly lower with atogepant (12.1%) compared to topiramate (29.6%), representing a relative risk of 0.41 (95% CI: 0.28, 0.59; p<0.0001).1 The study also met all six secondary endpoints, including a key measure of clinical efficacy: 64.1% of patients on atogepant achieved a ≥50% reduction in mean monthly migraine days (MMD) during months 4 to 6 of the double-blind treatment period compared to 39.3% of patients on topiramate (p<0.0001).1 'These TEMPLE data affirm recommendations from the American Headache Society and International Headache Society, highlighting the role of CGRP pathway inhibitors as first-line preventive treatment options for migraine,' said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. 'This study demonstrates our commitment to improving treatment options and advancing care standards for people living with this debilitating disease.' Migraine continues to be underdiagnosed and undertreated, despite significant burden on patients' lives.2 It is a complex neurological disease that affects approximately 14% of the global population and ranks as the second leading cause of disability worldwide.2 Despite its prevalence and disabling impact, there are numerous gaps in patient care related to the standards for preventive treatment. Notably, over 50% of people currently using preventive medications still qualify for further preventive treatment, indicating that their current therapies may not be providing sufficient relief.3 'Far too often, people living with migraine struggle with meeting their treatment goals despite available and accessible preventive options,' said Jaclyn Duvall, M.D., neurologist and founder of Headache Specialists of Oklahoma. 'The TEMPLE data provide a patient-centered measure of treatment effectiveness by capturing both efficacy and tolerability, representing a meaningful way to evaluate the real-world impact of treatment persistence in migraine prevention.' The AE profile of atogepant observed in this active-controlled study was generally consistent with its established safety profile from prior studies.1 Atogepant, marketed as AQUIPTA® in the EU and QULIPTA® in the U.S., Canada, Israel and Puerto Rico, is approved in 60 countries. Atogepant is a once-daily oral CGRP receptor antagonist, proven to prevent both episodic and chronic migraine in adults. Full results from the TEMPLE study will be presented at an upcoming medical meeting. About the TEMPLE Study TEMPLE is a Phase 3, multicenter, randomized, double-blind, active-controlled trial evaluating the tolerability, safety, and efficacy of atogepant versus topiramate in adult patients with a history of four or more migraine days per month. The trial randomized 545 participants with episodic or chronic migraine aged 18 and older across 73 sites in Europe, Israel and Canada. The study was conducted in two distinct periods. In the initial 24-week Double-Blind Treatment Period, which included a 6-week up-titration phase and an 18-week maintenance phase, participants were randomized to receive either atogepant (60 mg once daily) or the highest tolerated dose of topiramate (ranging from 50 to 100 mg/day). Following this, eligible participants continued into a 52-week Open-Label Treatment Period, during which all received atogepant (60 mg once daily). Throughout the study, patient reported outcomes were regularly collected and patients were continuously monitored for safety and tolerability through clinical assessments and lab tests. The primary endpoint was the percentage of patients who discontinued the study treatment due to AEs during the 24-week double-blind treatment period. An electronic diary (eDiary) was used to collect data on headache frequency, duration, symptoms, acute medication use, and various patient-reported outcomes. More information on the TEMPLE trial can be found on (NCT05748483). About Atogepant Atogepant is a once-daily orally administered CGRP receptor antagonist specifically developed for the preventive treatment of migraine in adults. CGRP and its receptors are expressed in regions of the nervous system associated with migraine pathophysiology. Studies have shown that CGRP levels are elevated during migraine attacks. Atogepant, marketed as AQUIPTA® in the EU and QULIPTA® in the U.S., Canada, Israel and Puerto Rico, is approved in 60 countries. U.S. Uses and Important Safety Information What is QULIPTA® (atogepant)? QULIPTA is a prescription medicine used for the preventive treatment of migraine in adults. IMPORTANT SAFETY INFORMATION FOR QULIPTA® Do not take QULIPTA if you have had an allergic reaction to atogepant or any ingredients in QULIPTA. Before taking QULIPTA, tell your healthcare provider about all your medical conditions, including if you: Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. QULIPTA may affect the way other medicines work, and other medicines may affect how QULIPTA works. Your healthcare provider may need to change the dose of QULIPTA when taken with certain other medicines. QULIPTA can cause serious side effects, including: The most common side effects of QULIPTA are nausea, constipation, and fatigue/sleepiness. These are not all the possible side effects of QULIPTA. QULIPTA is available in 10 mg, 30 mg, and 60 mg tablets. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit to learn more. Please see full Prescribing Information. Globally, prescribing information varies; refer to the individual country product label for complete information. About AbbVie in Migraine At AbbVie, we are committed to empowering people living with migraine disease. We advance science that enables healthcare providers to care for people impacted across the spectrum of migraine. Through education and partnerships with the migraine community, we strive to help those with migraine navigate barriers to care, access effective treatments, and reduce the impact of migraine on their lives. In the United States, AbbVie is the only company with three prescription treatments designed to meet patient needs across the spectrum of migraine to help patients living with this debilitating disease. About AbbVie AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at Follow @abbvie on LinkedIn,Facebook, Instagram, X (formerly Twitter), and YouTube. Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words 'believe,' 'expect,' 'anticipate,' 'project' and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, 'Risk Factors,' of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. ALL-NEUR-250043 Contact(s): Global Media: Amber Landis +1 (231) 557-6596 [email protected] U.S. Media: Sara Sanders +1 (973) 307-6145 [email protected] References View original content: SOURCE AbbVie
